Login to Your Account

AAN Roundup

Monday, April 30, 2012

• Chelsea Therapeutics International Ltd., of Charlotte, N.C., said that in its randomized, double-blind, placebo-controlled trial (Study 301), Northera (droxidopa) showed statistical improvement compared to placebo for neogenic orthostatic hypotension.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription